Allogeneic T lymphocyte clones derived from rejected human kidney produce high levels of a new lymphokine active on murine interleukin 3-sensitive cell lines.
Moreau
J F
JF
Laboratoire d'Immunologie Clinique Institut National de la Sante et de la Recherche Medicale (INSERM) U211, Nantes, France.
Bonneville
M
M
Godard
A
A
Peyrat
M A
MA
Capron
M
M
Moore
M A
MA
Soulillou
J P
JP
D002478:Cells, Cultured; D002634:Chemotaxis, Leukocyte / Q000187:drug effects; D002999:Clone Cells; D004804:Eosinophils / Q000276:immunology / Q000502:physiology; D006084:Graft Rejection / Q000276:immunology*; D006131:Growth Inhibitors; D006801:Humans; D015850:Interleukin-6; D016030:Kidney Transplantation / Q000276:immunology*; D053605:Leukemia Inhibitory Factor; D008163:Luminescent Measurements; D008222:Lymphokines / Q000096:biosynthesis* / Q000302:isolation & purification / Q000494:pharmacology; D009504:Neutrophils / Q000276:immunology / Q000502:physiology; D013601:T-Lymphocytes / Q000276:immunology*
D006131:Growth Inhibitors; D015850:Interleukin-6; C507837:LIF protein, human; D053605:Leukemia Inhibitory Factor; D008222:Lymphokines